| Tbio | Kinase suppressor of Ras 2 |
Location-regulated scaffold connecting MEK to RAF. Has very low protein kinase activity and can phosphorylate MAP2K1 at several Ser and Thr residues with very low efficiency (in vitro). Interaction with BRAF enhances KSR2-mediated phosphorylation of MAP2K1 (in vitro). Blocks MAP3K8 kinase activity and MAP3K8-mediated signaling. Acts as a negative regulator of MAP3K3-mediated activation of ERK, JNK and NF-kappa-B pathways, inhibiting MAP3K3-mediated interleukin-8 production.
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Obesity, Morbid | 7 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| lung carcinoma | 2843 | 1.6e-37 |
| glioblastoma | 5792 | 1.4e-10 |
| Astrocytoma, Pilocytic | 3081 | 2.4e-07 |
| medulloblastoma, large-cell | 6241 | 4.2e-07 |
| group 3 medulloblastoma | 4104 | 4.5e-07 |
| oligodendroglioma | 2850 | 1.6e-06 |
| adult high grade glioma | 3801 | 2.1e-06 |
| atypical teratoid / rhabdoid tumor | 5112 | 1.3e-05 |
| primitive neuroectodermal tumor | 3035 | 8.7e-05 |
| interstitial cystitis | 2312 | 6.2e-04 |
| astrocytic glioma | 2597 | 8.8e-03 |
| subependymal giant cell astrocytoma | 2287 | 9.4e-03 |
| ependymoma | 4679 | 2.9e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Acquired metabolic disease | 336 | 0.0 | 0.8 |
| Endometriosis | 540 | 0.0 | 0.9 |
| Disease | log2 FC | p |
|---|---|---|
| adult high grade glioma | -3.200 | 2.1e-06 |
| astrocytic glioma | -1.700 | 8.8e-03 |
| Astrocytoma, Pilocytic | -2.600 | 2.4e-07 |
| atypical teratoid / rhabdoid tumor | -2.900 | 1.3e-05 |
| ependymoma | -1.400 | 2.9e-02 |
| glioblastoma | -3.200 | 1.4e-10 |
| group 3 medulloblastoma | -4.300 | 4.5e-07 |
| interstitial cystitis | -2.100 | 6.2e-04 |
| lung carcinoma | 2.000 | 1.6e-37 |
| medulloblastoma, large-cell | -3.700 | 4.2e-07 |
| oligodendroglioma | -1.200 | 1.6e-06 |
| primitive neuroectodermal tumor | -2.600 | 8.7e-05 |
| subependymal giant cell astrocytoma | -2.954 | 9.4e-03 |
MDEENMTKSEEQQPLSLQKALQQCELVQNMIDLSISNLEGLRTKCATSNDLTQKEIRTLESKLVKYFSRQ 1 - 70 LSCKKKVALQERNAELDGFPQLRHWFRIVDVRKEVLEEISPGQLSLEDLLEMTDEQVCETVEKYGANREE 71 - 140 CARLNASLSCLRNVHMSGGNLSKQDWTIQWPTTETGKENNPVCPPEPTPWIRTHLSQSPRVPSKCVQHYC 141 - 210 HTSPTPGAPVYTHVDRLTVDAYPGLCPPPPLESGHRSLPPSPRQRHAVRTPPRTPNIVTTVTPPGTPPMR 211 - 280 KKNKLKPPGTPPPSSRKLIHLIPGFTALHRSKSHEFQLGHRVDEAHTPKAKKKSKPLNLKIHSSVGSCEN 281 - 350 IPSQQRSPLLSERSLRSFFVGHAPFLPSTPPVHTEANFSANTLSVPRWSPQIPRRDLGNSIKHRFSTKYW 351 - 420 MSQTCTVCGKGMLFGLKCKNCKLKCHNKCTKEAPPCHLLIIHRGDPARLVRTESVPCDINNPLRKPPRYS 421 - 490 DLHISQTLPKTNKINKDHIPVPYQPDSSSNPSSTTSSTPSSPAPPLPPSATPPSPLHPSPQCTRQQKNFN 491 - 560 LPASHYYKYKQQFIFPDVVPVPETPTRAPQVILHPVTSNPILEGNPLLQIEVEPTSENEEVHDEAEESED 561 - 630 DFEEMNLSLLSARSFPRKASQTSIFLQEWDIPFEQLEIGELIGKGRFGQVYHGRWHGEVAIRLIDIERDN 631 - 700 EDQLKAFKREVMAYRQTRHENVVLFMGACMSPPHLAIITSLCKGRTLYSVVRDAKIVLDVNKTRQIAQEI 701 - 770 VKGMGYLHAKGILHKDLKSKNVFYDNGKVVITDFGLFSISGVLQAGRREDKLRIQNGWLCHLAPEIIRQL 771 - 840 SPDTEEDKLPFSKHSDVFALGTIWYELHAREWPFKTQPAEAIIWQMGTGMKPNLSQIGMGKEISDILLFC 841 - 910 WAFEQEERPTFTKLMDMLEKLPKRNRRLSHPGHFWKSAEL 911 - 950 //
